Amrize vs Eagle Materials
AMRZ and EXP side by side, both in materials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRZ and EXP compare
Amrize is the larger company, worth 4.0 times as much as Eagle Materials ($22.6B against $5.6B).
On earnings, Eagle Materials is cheaper: it trades at 14.5× trailing earnings, against 18.2× for Amrize.
Amrize grew revenue faster over the last twelve months (3.5% versus 1.7% for Eagle Materials).
Eagle Materials keeps more of each dollar of sales as profit, with a net margin of 17.3% compared with 10.2% at Amrize.
Both pay dividends: Amrize yields 1.6% and Eagle Materials 0.54%.
Eagle Materials scores higher on the StockData Score (12 against 10 for Amrize), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRZ | EXP |
|---|---|---|
| Size and price | ||
| Market cap | $22.6B | $5.6B |
| Share price | $41.38 | $183.64 |
| Change, 1 year | −21.7% | −21.2% |
| Change, 5 years | – | 18.0% |
| Beta (5Y) | 0.73 | 1.14 |
| Employees | 19K | 2,800 |
| StockData Score | ||
| Total score | 10 | 12 (better) |
| Valuation score | 3 | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 4 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | 18.2× | 14.5× (better) |
| P/S | 1.8× (better) | 2.4× |
| P/B | 1.8× (better) | 3.8× |
| EV/EBITDA | 10.2× | – |
| P/FCF | 21.0× (better) | 33.0× |
| PEG | – | 7.90 |
| FCF yield | 4.8% (better) | 3.0% |
| Fair value | $47.20 | $201.06 |
| Margin of safety | 12.3% (better) | 8.7% |
| Growth | ||
| Revenue growth (TTM) | 3.5% (better) | 1.7% |
| Revenue growth, 5Y average | – | 7.3% |
| Net income growth (TTM) | 8.3% (better) | −11.1% |
| EPS growth (TTM) | 8.6% (better) | −6.8% |
| EPS growth, 5Y average | – | 10.1% |
| Profitability | ||
| Gross margin | 24.8% | 27.0% (better) |
| Operating margin | 15.5% | – |
| Net margin | 10.2% | 17.3% (better) |
| FCF margin | 8.8% (better) | 7.3% |
| Return on equity | 9.8% | 27.0% (better) |
| Return on invested capital | 9.7% | – |
| Financial health | ||
| Debt / equity | 0.46 (better) | 1.18 |
| Net debt / EBITDA | 2.00 | – |
| Interest coverage | 5.3× | – |
| Current ratio | 1.07 | 3.23 (better) |
| Altman Z-score | 2.03 | 2.72 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.6% (better) | 0.54% |
| Payout ratio | – | 8.0% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 58.5% |
| Buyback yield | – | 6.9% |
| Shareholder yield | 1.6% | 7.4% (better) |
| Ownership | ||
| Held by institutions | 47.1% | 108% |
| Held by insiders | 7.4% | 1.2% |
| Insider net buying, 12 months | $10.2M (better) | −$1.5M |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 2.2% | 6.2% |
Go deeper
- AMRZ stock overview
- AMRZ income statement
- AMRZ valuation and score
- EXP stock overview
- EXP income statement
- EXP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.